Peptides for cyclists: the aerobic capacity approach

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

This article discusses the application of peptides in athletic performance. It covers specific protocols and their clinical implications for various sports.

Peptides for Cyclists: The Aerobic Capacity Approach

VO2 max, a critical marker of aerobic capacity, typically ranges from 40-50 mL/kg/min for recreational cyclists, but elite athletes can push beyond 70 mL/kg/min. Enhancing this number can significantly improve endurance and performance. Peptide therapy offers targeted ways to boost aerobic capacity by improving mitochondrial function, oxygen delivery, and recovery.

Why Aerobic Capacity Matters for Cyclists

Aerobic capacity dictates how efficiently your body uses oxygen during prolonged exercise. For cyclists, a high VO2 max means better stamina, faster recovery, and greater power output over long distances. Improving VO2 max by even 5-10% can translate to noticeable race-day benefits.

Key Peptides for Enhancing Aerobic Capacity

• Ipamorelin + CJC-1295 (without DAC): A growth hormone secretagogue combination that stimulates pulsatile GH release. Typical dosing is 100mcg of each peptide subcutaneously, twice daily for 12 weeks. This combo improves muscle repair, mitochondrial biogenesis, and fat metabolism, indirectly supporting aerobic capacity (Friedman et al., 2017).
• Thymosin Beta-4 (TB-500): Administered at 2mg twice weekly for 6 weeks, TB-500 promotes angiogenesis and tissue repair, which helps increase capillary density in muscle tissue—key for oxygen delivery during endurance cycling (Malinda et al., 1997).
• BPC-157: Given at 250mcg daily for 4 weeks, BPC-157 enhances tendinous and muscle healing, enabling more consistent training with less downtime (Sikiric et al., 2018).
• MOTS-c: A mitochondrial-derived peptide dosed at 10mg daily in experimental settings, MOTS-c supports mitochondrial metabolism and improves glucose utilization, which may enhance aerobic endurance (Lee et al., 2015).

Mechanisms Behind Peptide Benefits

Ipamorelin and CJC-1295 stimulate endogenous growth hormone (GH) release without the desensitization seen in synthetic GH injections. Pulsatile GH spikes encourage IGF-1 production, promoting muscle repair and increasing oxidative muscle fibers, which rely more on aerobic metabolism.

Thymosin Beta-4 supports new capillary formation (angiogenesis), improving oxygen diffusion to working muscles. Greater capillary density reduces reliance on anaerobic glycolysis—a key factor in delaying fatigue during long rides.

BPC-157's role in collagen synthesis and tendon repair helps cyclists maintain consistent training volumes by preventing overuse injuries, which indirectly supports aerobic capacity by allowing uninterrupted training adaptations.

MOTS-c enhances mitochondrial function by activating AMPK and promoting fatty acid oxidation, key for endurance athletes who rely on efficient energy production over extended periods.

Ipamorelin + CJC-1295 vs Synthetic Growth Hormone

• Safety: Secretagogues like Ipamorelin/CJC-1295 stimulate physiological GH release, lowering risks of acromegaly or insulin resistance compared to synthetic GH.
• Effect Duration: Secretagogues require daily or twice-daily injections to maintain GH pulses, whereas synthetic GH can be dosed less frequently but with a less natural hormone profile.
• Cost: Secretagogues are generally more affordable and accessible for long-term use.

Clinical Nuances and Limitations

While many cyclists experience improved recovery and endurance with these peptides, individual responses vary. For instance, those with pre-existing GH axis dysfunction may see more pronounced effects from Ipamorelin/CJC-1295. Conversely, athletes with optimal baseline mitochondrial function may gain less from MOTS-c supplementation.

Moreover, dosing precision matters. Overuse of growth hormone secretagogues can blunt natural GH pulsatility, while underdosing may produce negligible benefits. Monitoring IGF-1 levels every 4-6 weeks is recommended, aiming for mid-normal lab ranges (150-300 ng/mL) to avoid adverse effects.

Supporting Peptide Therapy with Clinical Monitoring

• Baseline labs: IGF-1, fasting insulin, HbA1c, and lipid profile.
• Follow-up every 4-6 weeks to adjust doses and monitor side effects.
• Functional testing: periodic VO2 max or lactate threshold testing to quantify improvements.
• Symptom tracking: fatigue, recovery time, and injury incidence.

Actionable Clinical Takeaway

For cyclists aiming to improve aerobic capacity, initiating Ipamorelin 100mcg plus CJC-1295 (no DAC) 2x daily for 12 weeks alongside BPC-157 250mcg daily can enhance recovery and endurance. Adding Thymosin Beta-4 2mg twice weekly during intense training blocks supports vascular adaptations critical for oxygen delivery. Monitor IGF-1 levels to maintain them within 150-300 ng/mL, adjust dosing accordingly, and consider MOTS-c for mitochondrial support in cases of plateaued aerobic performance. This peptide protocol, paired with targeted clinical labs and functional testing, offers a nuanced, evidence-informed strategy to optimize cycling endurance.